CoChat

Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Purpose: Osteosarcoma (OS) is the most common primary bone tumor. Despite complete surgical removal and intensive chemotherapeutic treatment, 30%-35% of patients with OS have local or systemic recurrence. Some patients survive multiple recurrences, but overall survival after OS recurrence is poor. This analysis aims to describe and identify factors influencing post-relapse survival (PRS) after a second OS relapse. Methods: This is a retrospective analysis of 60 patients with a second relapse of OS of the extremities in 2 Italian centers between 2003 and 2013. Results: Treatment for first and subsequent relapses was planned according to institutional guidelines. After complete surgical remission (CSR) following the first recurrence, patients experienced a second OS relapse with a median disease-free interval (DFI) of 6 months. Lung disease was prevalent: 44 patients (76%) had pulmonary metastases. Survival after the second relapse was 22% at 5 years. Lung disease only correlated with better survival at 5 years (33.6%) compared with other sites of recurrence (5%; p = 0.008). Patients with a single pulmonary lesion had a better 5-year second PRS (42%; p = 0.02). Patients who achieved a second CSR had a 5-year second PRS of 33.4%. Chemotherapy (p<0.001) benefited patients without a third CSR. Conclusions: This analysis confirms the importance of an aggressive, repeated surgical approach. Lung metastases only, the number of lesions, DFI and CSR influenced survival. It also confirms the importance of chemotherapy in patients in whom surgical treatment is not feasible.

Overview

Integrity signals

Registry

Crossref · 10.1177/0300891617753257

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 18 · Cited by 31

Research works printed but not linked: 3

  1. Raymond AK, 2002, World Health Organization Classification of Tumours. Tumours of soft tissue and bone, 264
  2. ESMO/European Sarcoma Network Working Group, 2014, Ann Oncol, 25
  3. Paioli A, Book of Abstracts, 27th Annual Meeting of the European Musculo-Skeletal Oncology Society (EMSOS)

Metadata

Authors
Tirtei, E., Asaftei, S. D., Manicone, R., Cesari, M., Paioli, A., Rocca, M., Ferrari, S., & Fagioli, F.
Affiliations
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Istituto Ortopedico Rizzoli (IT)
Corresponding author
Tirtei, Elisa
Venue
Tumori Journal
Published
2018-06
Volume
104
Issue
3
Pages
202-206
ISSN
  • 0300-8916 (ISSN-L)
  • 2038-2529
OpenAlex
W4256385699
Cited by
31
References
18
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 3
FWCI
2.04
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Tumori Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
osteosarcoma, second relapse, survival after relapse, lung metastasis, disease-free interval, chemotherapy, limb-sparing surgery, prognostic factors, extremity osteosarcoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. https://app.cochat.ai/papers/10.1177/0300891617753257
The paper
Tirtei, E., Asaftei, S. D., Manicone, R., Cesari, M., Paioli, A., Rocca, M., Ferrari, S., & Fagioli, F. (2018). Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori Journal. https://doi.org/10.1177/0300891617753257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.